New ICD-11 diagnostic criteria for chronic secondary musculoskeletal pain associated with Parkinson disease
2 Brustzentrum Kantonsspital St.Gallen
3 Neuro-Dol - Neuro-Dol
4 CHU Clermont-Ferrand
5 King‘s College London
6 NHS Foundation Trust [London]
7 Inselspital - Bern University Hospital [Berne]
8 Balgrist University Hospital
9 Uniklinik Essen - Universitätsklinikum Essen = University Hospital Essen [Universität Duisburg-Essen]
10 Service Neurologie [CHU Clermont-Ferrand]
11 IP - Institut Pascal
12 NPsy-Sydo - Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux
13 TGI - Thérapie guidée par l'image
14 Image Guided Clinical Neurosciences and Connectomics (IGCNC)
15 UCA - Pontificia Universidad Católica Argentina (Universidad Católica Argentina) [Buenos Aires, Argentina] = Pontifical Catholic University of Argentina = Université catholique argentine
16 Kantonsspital St.Gallen [Schweiz] = St.Gallen Cantonal Hospital [switzerland] = Hôpital cantonal de Saint-Gall [Suisse]
17 UNILU - Université de Lucerne = Universität Luzern
18 KCH - King's College Hospital
19 Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
20 UNIVR - Università degli studi di Verona = University of Verona
21 CIC 1436 - Centre d'investigation clinique de Toulouse
22 ToNIC - Toulouse NeuroImaging Center
23 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
24 Universität Heidelberg [Heidelberg] = Heidelberg University
25 AAU - Aalborg University
- Fonction : Auteur
- PersonId : 1422110
- ORCID : 0000-0002-0900-0491
- Fonction : Auteur
- PersonId : 769113
- IdHAL : xavier-moisset
- ORCID : 0000-0002-8799-0750
- Fonction : Auteur
- PersonId : 743222
- IdHAL : ana-marques
- ORCID : 0000-0003-2428-4899
Résumé
Background: Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by frequent use of immunosuppressive drugs. Consequently, concerns have arisen about the potential increased risk of cancer in PwMS and how patients should be screened and managed in terms of cancer risk. Objective: To develop evidence-based recommendations to manage the coexistence of cancer and multiple sclerosis (MS). Methods: The French Group for Recommendations in MS collected articles from PubMed and university databases covering the period January 1975 through June 2022. The RAND/UCLA method was employed to achieve formal consensus. MS experts comprehensively reviewed the full-text articles and developed the initial recommendations. A group of multidisciplinary health care specialists then validated the final proposal. Results: Five key questions were addressed, encompassing various topics such as cancer screening before or after initiating a disease-modifying therapy (DMT), appropriate management of MS in the context of cancer, recommended follow-up for cancer in patients receiving a DMT, and the potential reintroduction of a DMT after initial cancer treatment. A strong consensus was reached for all 31 recommendations. Conclusion: These recommendations propose a strategic approach to managing cancer risk in PwMS.